CD40LG and neoplasm: AGS-003 (Rocapuldencel-T), an autologous MoDC vaccine, loaded with the patient’s tumor-derived RNA in combination with CD40-ligand RNA, co-administered with sunitinib, an ICB, showed promising results in a phase 2 clinical trial in subjects newly diagnosed with advanced kidney cancer [83, 84].